Clinical Trial Update: R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 trial update for R-BMD in refractory or relapsed lymphoma (GELTAMO), completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• R-BMD (R-BMD)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-11-01